Zenara Pharma receives Nirmatrelvir and Ritonavir tablets

Hyderabad, July 28

Zenara Pharma, a subsidiary of Biophore India Pharmaceuticals, has received approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market Nirmatrelvir and Ritonavir tablets in a combination pack as a treatment option for patients with symptoms mild to moderate Covid-19.

The tablets, which will be sold under the brand name “Paxzen”, are manufactured at Zenara’s US FDA-approved facility in Hyderabad.

“We plan to launch Paxzen in the coming weeks and are in talks with several institutions and hospitals in India to ensure the product is readily available to patients in need,” said Srinivas Arutla, CEO of Zenara Pharma.

“This approval by CDSCO has been granted under the emergency clearance pathway considering the unmet medical need in Covid-19 for an effective and affordable therapy for patients in India,” said Jagadeesh Babu Rangisetty , co-founder and CEO of Zenara Pharma, said.

“We believe Paxzen is an extremely effective treatment option for Covid-19. It is a very complex product to develop and manufacture. We brought this product to market in record time, and this is one of the first approvals of this product in India,” he said in a statement on Thursday.

The product, being the first oral pill, received FDA approval in December 2021 in the United States.

Published on

July 28, 2022

About Margie Peters

Check Also

Triastek and Eli Lilly team up to 3D print gastrointestinal drugs

Chinese drug 3D printing company Triastek announced a partnership with a global pharmaceutical company Eli …